Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) prior to securing employment at Caltech.-First employee and co-founder of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures).-Remains an avid investor, focused on market trends and especially biotechnology stocks.Analyst’s Disclosure: I/w ...

Its future is bright, but that doesn't mean it'll always be smooth sailing.While Amgen's (AMGN -4.16%) shares have underperformed the market over the past 12 months, climbing 19.7% compared to the market's unusually large gain of 35.6%, there's no shortage of reasons to buy its stock. Still, there is a risk that could rain on the biotech's parade a bit over the next couple of years.Let's examine two reasons why the stock is worth buying, and one reason why it makes sense to be just a little bit cautious wit ...

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) --  Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amgen Inc. (NASDAQ: AMGN) on behalf of long-term stockholders following a class action complaint that was filed against Amgen on March 13, 2023 with a Class Period from July 29, 2020 and April 27, 2022. Our investigation concerns whether the board of directors of Amgen have breached their fiduciary duties to the company. Amgen is one of the ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry. Register now to see our 7 Best Stocks for the Next 30 Days report - free today! Amgen (AMGN) , in a press release, dismissed recent concerns that its obesity candidate, MariTide, may cause loss of bone mineral density ("BMD"). Some analysts at a global financial services firm claimed that a revie ...

Amgen Inc. (NASDAQ:AMGN) UBS Global Healthcare Conference November 13, 2024 1:15 PM ET Company Participants Peter Griffith - CFO Narimon Honarpour - SVP, Global Development Justin Claeys - VP, IR Conference Call Participants Trung Huynh - UBS Trung Huynh Okay, great. I think that's quarter past. Good morning, everyone. My name is Trung Huynh, I'm the large cap pharma, biopharma analyst here at UBS. It's my great pleasure to welcome team Amgen. We've got Peter Griffith here, CFO of the company. We're also jo ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday, following reports that the company’s weight-loss drug, MariTide, triggers a significant loss in bone density. Last seen holding above $300, AMGN could be due for more chart recovery if past is precedent.Specifically, Amgen stock pulled back to within one standard deviation of its 320-day moving average during yesterday's negative price action. Per Schaeffer's Senior Quantitative Analyst ...

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug.On Wednesday, Amgen Inc AMGN stated the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data, saying, “Amgen does not see an association between the administration of MariTide and bone mineral density (BMD) changes. The Phase 1 study results do not suggest any bone safety concerns or change our conviction in the promise of MariT ...

CHINA - 2024/09/17: In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo Illustration by Alvin Chan/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesAmgen stock (NASDAQ: AMGN) saw a 7% fall on Tuesday, November 12, after an update on the progress with its weight-loss drug — MariTide. An early-stage trial for the drug showed loss of bone density, which could be a potential safety risk. MariTide is an important ...

THOUSAND OAKS, Calif., Nov. 13, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data."As previously stated, Amgen does not see an association between the administration of MariTide and bone mineral density changes. The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. We look forward to sharing the Phase 2 topline data later this year."Amgen Forwar ...

Statistically Significant Reduction in Nasal Polyp Size, Nasal Congestion Compared to PlaceboTHOUSAND OAKS, Calif., Nov. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial demonstrated patients treated with TEZSPIRE® (tezepelumab-ekko) had a statistically significant and clinically meaningful reduction in the size of nasal polyps and ...